e-learning
resources
Munich 2006
Monday 04.09.2006
Biology and prognostic factors
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC)
D. Dworakowska, A. Karmolinski, E. Jassem, J. Jassem, M. Lapinski, D. Tomaszewski, K. Jaskiewicz, S. Yla-Herttuala, J. Skokowski, E. Czestochowska, K. Sworczak (Gdansk, Poland; Kuopio, Finland)
Source:
Annual Congress 2006 - Biology and prognostic factors
Session:
Biology and prognostic factors
Session type:
Poster Discussion
Number:
2294
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Dworakowska, A. Karmolinski, E. Jassem, J. Jassem, M. Lapinski, D. Tomaszewski, K. Jaskiewicz, S. Yla-Herttuala, J. Skokowski, E. Czestochowska, K. Sworczak (Gdansk, Poland; Kuopio, Finland). Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC). Eur Respir J 2006; 28: Suppl. 50, 2294
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Prognostic value of apoptotic index in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 5s
Year: 2004
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Actual challenges in thoracic surgery
Year: 2010
The expression of central cell cycle regulators in non-small cell lung cancer has therapy-dependent prognostic impact
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Staging of lung cancer
Year: 2010
Prognostic parameters in non-small cell lung cancer (211 cases)
Source: Eur Respir J 2002; 20: Suppl. 38, 268s
Year: 2002
Prognostic value of p21 protein expression in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Composite anatomical–clinical–molecular prognostic model in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 136-142
Year: 2011
HER2/
Neu
overexpression as independent negative prognostic factor for non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
FEV
1
is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results
Year: 2011
Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC)
Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept